BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21889718)

  • 1. Hormonal modulation in the treatment of breast cancer.
    Adelson K; Germain D; Raptis G; Biran N
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):519-32, viii. PubMed ID: 21889718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer.
    Bodmer A; Castiglione-Gertsch M
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S28-37. PubMed ID: 21943985
    [No Abstract]   [Full Text] [Related]  

  • 4. Evolution of endocrine adjuvant therapy for early breast cancer.
    Lønning PE
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase in the context of breast and endometrial cancer. A review.
    Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
    Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bone disease in patients undergoing hormonal therapy for breast cancer.
    Mirza FS
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):549-62, viii. PubMed ID: 21889720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biomarkers of endocrine therapy-resistance in breast cancers].
    de Cremoux P; Debled M; Bonnefoi H; Cottu P
    Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
    Chang J; Fan W
    Anticancer Agents Med Chem; 2013 Mar; 13(3):464-75. PubMed ID: 22931419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors: future directions.
    Osborne CK; Schiff R
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent topics in endocrine therapy for hormone-dependent breast cancer: basic research and clinical applications.
    Kimijima I
    Breast Cancer; 2008; 15(4):253-5. PubMed ID: 18953680
    [No Abstract]   [Full Text] [Related]  

  • 17. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surviving resistance to hormone therapy in hormone-dependent metastatic breast carcinoma].
    Tesarova P
    Klin Onkol; 2012; 25(6):486-8. PubMed ID: 23346638
    [No Abstract]   [Full Text] [Related]  

  • 19. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.